Table 1.
Major studies investigating the efficacy of treatment for biopsy-proven liver fibrosis in relation to hepatitis virus infection
| Liver disease | Drugs | Study design | No. of patients | Effects | Reference |
|---|---|---|---|---|---|
| HBV | Peginterferon | Non RCT | 110 | 27% Fibrosis improvement (16-month F/U) | [72] |
| Lamivudine | Non RCT | 63 | 73% Fibrosis improvement (F4 to F2-3, 36-month F/U) | [73] | |
| Entecavir | Non RCT | 57 | 88% Fibrosis improvement (65-month F/U) | [74] | |
| Tenofovir | Non RCT | 348 | 51% Fibrosis improvement (60-month F/U) | [75] | |
| HCV | Peginterferon and ribavirin | Non RCT | 60 | 82% Fibrosis improvement (60-monthF/U) | [76] |
| Angiotensin II type 1 receptor blocker (losartan) | Non RCT | 14 | 50% Fibrosis improvement (18-month F/U) | [81] | |
| PPAR-γ agonist (Farglitazar) | RCT | 109 | No fibrosis improvement (18-month F/U) | [82] |
HBV, hepatitis B virus; RCT, randomized controlled trial; F/U, follow-up; F4, METAVIR score, fibrosis score 4; HCV, hepatitis C virus; PPAR-γ, peroxisome proliferator-activated receptor γ.